Ke Sun

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Topics

Coronary Artery Bypass

Radiofrequency Ablation

Top Venues

Hepatology communications

This page only lists publications with an associated author ORCID identifier.

Publications

Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)
Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen, Jianpeng Sheng, Xing Huang, Jun-Hui Sun, Wen-Bo Xiao, Ke Sun, Shunliang Gao, Risheng Que, Yan Shen, Min Zhang, Jian Wu, Xue-Li Bai, Jianpeng Sheng
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology communications 7 (3) (2023)